OTLC · Oncotelic Therapeutics, Inc.
$0.02
+0.00 (+11.45%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing.”View the 10-Q filed Aug 13, 2026
Market Cap
$9.15M
Shares
457.51M
Volume · Oct 19
204.6K
Avg daily vol (3M)
308.57K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.02
Day$0.02–0.02
52W close$0.02–0.11
Avg vol 30d428K
Short int16K · 0.0% float · 1.0d
Short vol66%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$247.58M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-9,497.2%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 2,705.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$2.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.3%
Year over year · more shares
Price change (1Y)
-81.6%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−58%
below
Price vs 50-day avg
−35%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−54%
trailing
YTD return
−77%
this year
Relative strength
−61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +20.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
29
low risk · 0–100
Fundamentals
Revenue growth
−96%
Y/Y
EPS growth
+6000%
Y/Y
Free cash flow
$-1.4M
Quant / Vol
risk profile
Volatility
148%
annualized · 1-yr
Max drawdown
−85%
past year
ATR
15.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−58%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +20.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 2%
Range high $0
vs 200-day avg -58%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OTLC
this stock
Oncotelic Therapeutics, Inc.
|
$9.15M | -76.9% | -39.1% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.0%
- Net QoQ
- +61.2K sh
- Top holder
- IFP Advisors, Inc
Held
Float
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 13, 2026
- This year
- 19
Oncotelic Therapeutics presented its PDAOAI platform and hepatocellular carcinoma research at Drug Discovery 2026. PDAOAI indexes approximately 29 million PubMed abstracts, while a four-gene mTOR-related signature showed retrospective survival associations that do not establish treatment benefit.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OTLC | -7.5% | -26.6% | -53.8% | -15.9% | -76.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -6.0% | -25.7% | -61.5% | -16.4% | -89.3% |